Effects of withdrawing erythropoietin.
作者信息
Taylor J E, Henderson I S, Mactier R A, Stewart W K
机构信息
Renal Unit, Ninewells Hospital and Medical School, Dundee.
出版信息
BMJ. 1991 Feb 2;302(6771):272-3. doi: 10.1136/bmj.302.6771.272-a.
Abstract
摘要
相似文献
1
Effects of withdrawing erythropoietin.停用促红细胞生成素的影响。
BMJ. 1991 Feb 2;302(6771):272-3. doi: 10.1136/bmj.302.6771.272-a.
2
[Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
Nefrologia. 2001;21(6):606-7.
3
[Therapy of renal anemia with recombinant human erythropoietin].重组人促红细胞生成素治疗肾性贫血
Dtsch Med Wochenschr. 1988 Jan 29;113(4):125-9. doi: 10.1055/s-2008-1067605.
4
Occult infection and resistance of anaemia to rHuEpo therapy in renal failure.
Nephrol Dial Transplant. 1990;5(3):232-4. doi: 10.1093/ndt/5.3.232.
5
The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.慢性肾衰竭贫血：病理生理学及重组促红细胞生成素的作用
Contrib Nephrol. 1990;78:24-36; discussion 37.
6
Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.通过血清促红细胞生成素检测监测慢性肾衰竭贫血的促红细胞生成素治疗。
Ann Clin Biochem. 1993 Mar;30 ( Pt 2):205-6. doi: 10.1177/000456329303000219.
7
Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.接受促红细胞生成素α治疗贫血的慢性肾衰竭患者的管理。
Transplant Proc. 1991 Apr;23(2):1831-2.
8
9
Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.次优剂量的重组人促红细胞生成素可显著降低血清铁蛋白水平。
Clin Lab Haematol. 1991;13(3):251-3. doi: 10.1111/j.1365-2257.1991.tb00280.x.
10
Once-weekly epoetin-beta in renal anemia: the clinical evidence.
Contrib Nephrol. 2002(137):408-11. doi: 10.1159/000060269.
引用本文的文献
1
Cost-utility analysis.成本效用分析。
BMJ. 1993 Nov 6;307(6913):1213. doi: 10.1136/bmj.307.6913.1213.
2
Picking up the tab for erythropoietin.为促红细胞生成素买单。
BMJ. 1991 Mar 9;302(6776):592.
3
Picking up the tab for erythropoietin.为促红细胞生成素买单。
BMJ. 1991 Feb 2;302(6771):248-9. doi: 10.1136/bmj.302.6771.248.
4
Picking up the tab for erythropoietin.承担促红细胞生成素的费用。
BMJ. 1991 Apr 13;302(6781):913. doi: 10.1136/bmj.302.6781.913-a.
5
The economics of prescribing.处方经济学
J R Coll Physicians Lond. 1992 Jan;26(1):66-8.
6
Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.低剂量皮下注射促红细胞生成素对终末期肾病贫血患者的成本效益
BMJ. 1992 Feb 22;304(6825):474-7. doi: 10.1136/bmj.304.6825.474.
本文引用的文献
1
Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.重组DNA衍生的人促红细胞生成素对维持性慢性血液透析患者贫血的影响。
Lancet. 1986 Nov 22;2(8517):1175-8. doi: 10.1016/s0140-6736(86)92192-6.
3
Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients.
Nephrol Dial Transplant. 1989;4(11):979-87. doi: 10.1093/ndt/4.11.979.
Zotero 插件